PaxMedica (PaxMedica) Short-Term Debt : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is PaxMedica Short-Term Debt?

PaxMedica's Short-Term Debt for the quarter that ended in Mar. 2024 was $0.00 Mil.

PaxMedica's quarterly Short-Term Debt declined from Sep. 2023 ($1.58 Mil) to Dec. 2023 ($0.00 Mil) but then stayed the same from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($0.00 Mil).

PaxMedica's annual Short-Term Debt increased from Dec. 2021 ($0.00 Mil) to Dec. 2022 ($0.17 Mil) but then declined from Dec. 2022 ($0.17 Mil) to Dec. 2023 ($0.00 Mil).

PaxMedica Short-Term Debt Historical Data

The historical data trend for PaxMedica's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PaxMedica Short-Term Debt Chart

PaxMedica Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

0.61

0.17

PaxMedica Quarterly Data
	Mar19	Jun19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															1.12	1.61	1.58	-	-

PaxMedica Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

PaxMedica Short-Term Debt Related Terms

Thank you for viewing the detailed overview of PaxMedica's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

PaxMedica (PaxMedica) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PaxMedica Inc (OTCPK:PXMD) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

303 South Broadway, Suite 125, Tarrytown, NJ, USA, 10591

Website

https://www.paxmedica.com

PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.

Executives

Zachary Rome	director, officer: Chief Operating Officer	C/O TIMBER PHARMACEUTICALS, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Michael Derby	director, officer: Executive Chairman	303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Howard J. Weisman	director, officer: Chief Executive Officer	C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Karen Larochelle	director	900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
John F Coelho	director	22 BENEDICT CRESCENT, BASKING RIDGE NJ 07920
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
David W. Hough	officer: Chief Medical Officer	C/O PAXMEDICA, INC., 900 E. HAMILTON AVENUE, SUITE 100, CAMPBELL CA 95008
Tardimed Sciences Llc	10 percent owner	303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591
Stephen Sheldon	officer: Chief Financial Officer	2 REVOLUTIONARY WAY, #312, HOPKINTON MA 01748